Pacific Edge Limited (PEB.AX)

0,0800 0,0000 (0,00%) Börsenschluss: 11:00AM AEST

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 114

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Peter Meintjes	Chief Executive Officer	N/A	N/A	N/A
Mr. Grant Gibson	Chief Financial Officer	N/A	N/A	N/A
Mr. Darrell Morgan	Chief Operating Officer	N/A	N/A	N/A
Dr. Justin Harvey	Chief Technology Officer	N/A	N/A	N/A
Prof. Parry Guilford Ph.D.	Chief Scientific Officer & Member of Scientific Advisory Board	122,02k	N/A	N/A
Mr. Jack Atchason	Senior Vice President of Sales - Pacific Edge Diagnostics USA Limited	N/A	N/A	N/A
Mr. Andrew McIntosh	Chief Digital Officer	N/A	N/A	N/A
Glen Costin	President of Asia Pacific	N/A	N/A	N/A
Dr. Tamer Aboushwareb	Chief Medical Officer	N/A	N/A	N/A
Mr. David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	48,26k	N/A	1960

Die Beträge haben den Stand 31. Dezember 2009 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limiteds ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 6, Vorstand: 2, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.